Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer-Reference-Cited by-同舟云学术

Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer

Published:2022-04-28 Issue:6 Volume:39 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Reyes Diane K.^ORCID,Trock Bruce J.,Tran Phuoc T.,Pavlovich Christian P.,Deville Curtiland,Allaf Mohamad E.,Greco Stephen C.,Song Daniel Y.,Bivalacqua Trinity J.,Han Misop,Partin Alan W.,Sartor A. Oliver,Rowe Steven P.,Pienta Kenneth J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12032-022-01662-7.pdf

Reference33 articles.

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.

2. Joice GA, Rowe SP, Pienta KJ, Gorin MA. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. Curr Opin Urol. 2017;27:533–41.

3. Goldberg H. Oligometastatic prostate cancer—treatment of the primary tumor and metastasis directed therapy. Invest Clin Urol. 2019;58:307–16.

4. NCCN Guidelines Version 3.2016 Prostate Cancer. National Comprehensive Cancer Network, 2016. (Accessed 11 Dec 2021, at https://www2.tri-kobe.org/nccn/guideline/archive/urological2016-2017/english/prostate.pdf).

5. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501–11.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer;European Urology;2024-08

2. Current Treatment Paradigms and Clinical Outcomes in Oligometastatic Prostate Cancer Patients: A Targeted Literature Review;European Urology Oncology;2024-07

3. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy;BMC Cancer;2024-05-25

4. Metastasis-directed therapy in oligometastatic prostate cancer;Current Opinion in Urology;2024-03-05

5. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies;European Urology;2024-02